The promise of novel bispecific antibody for patients with heavily-pretreated metastatic colorectal cancer: VHIO´s Guillem Argilés discusses preliminary data showing efficacy and favorable safety profile

During a Selected Abstracts Session entitled New Drugs in GI Cancer and Abstracts on Non-Colorectal Cancer at the recent European Society for Medical Oncology´s (ESMO) 19th World Congress on Gastrointestinal Cancer, 29 June – 01 July here in Barcelona, Spain, Guillem Argilés, Medical Oncologist and Clinical Investigator of VHIO´s Gastrointestinal & Endocrine Tumors Group headed by Josep Tabernero, presented preliminary clinical data from a trial designed to establish the efficacy of the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody either as monotherapy or in combination with atezolizumab for the treatment of patients with metastatic colorectal cancer (mCRC).

Oncology channel Onclive caught up with him during the Congress to discover just how treatment with CEA-TCB fared both as monotherapy and in combination with the selected PDL1 inhibitor in patients with mCRC. To access the interview with Guillem please click here.



Related Posts